What’s new from ASH 2024

Reed-sternberg,Cell,In,Hodgkin,Lymphoma,Front,View,3d,Render,Illustration

Novel agents are revolutionising Hodgkin Lymphoma treatment and outcomes; this report from the American Society of Haematology (ASH) Congress summarises some of these developments with a focus on brentuximab

Learning objectives:

You will learn about

  • The modern treatment of advanced Hodgkin Lymphoma using novel agents, such as brentuximab vedotin
  • The evolving role of brentuximab vedotin in the care of patients who develop R/R HL.

To access this module, please register or login: